



## Meda expands the collaboration with Recordati

Meda expands the collaboration with Recordati, a European pharma company based in Italy, by signing a long-term agreement for marketing a new combination product in Spain – one of the largest European markets. The combination product consists of lercanidipine (calcium antagonist) and enalapril (an ACE inhibitor) – two well-known pharmaceutical substances. The product is indicated for the treatment of high blood pressure.

Meda already has marketing rights for this combination product in Germany and Scandinavia. The product launch has started in Germany and will be registered in Spain through the mutual recognition procedure.

For more information:

Anders Lönner, CEO

phone +46 8 630 19 72

Anders Larnholt, Investor Relations

phone +46 709 458 878

---

**MEDA AB (publ)** is a leading European specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda has its own affiliates in 25 countries and more than 1,000 employees within marketing and sales. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit [www.meda.se](http://www.meda.se).